Argenx Commits $550 Million Upfront To Unnatural Products Deal — With Milestone Payments To Follow

The planned purchase adds peptide drug discovery to argenx’s antibody business, with potential oral and long-acting treatments.

Share
Argenx Commits $550 Million Upfront To Unnatural Products Deal — With Milestone Payments To Follow

Argenx, which develops antibody medicines for autoimmune diseases, agreed Monday to buy the remaining shares of Unnatural Products for $550 million upfront and milestone-linked payments, the company said in a statement. The deal values the biotech at up to approximately $1.15 billion and adds peptide drug discovery, which argenx says could help it develop oral and long-acting medicines for serious immune-mediated diseases.

$595 Million Depends On Milestones

Argenx plans to fund the upfront payment with cash on hand. Another up to $595 million would become payable if Unnatural Products reaches specified development and regulatory milestones.

The buyer already owns a minority stake in Unnatural Products, known as UNP. Their collaboration and investments predate the deal by more than two years. Both boards have approved the purchase.

Argenx’s market value stood at $58.3 billion at Friday’s close.

Peptides Join The Antibody Business

UNP uses machine learning and experiments run in parallel to discover and design macrocyclic peptides, a class of molecules it is developing against targets traditionally difficult to address with drugs. Argenx wants to combine those capabilities with its antibody engineering to expand the biology it can pursue.

Karen Massey, chief executive officer of argenx, said: “UNP adds macrocyclic peptide capabilities that are highly complementary to our antibody engineering and creates new possibilities for oral and long-acting medicines.”

Argenx’s existing business centers on VYVGART, which targets a protein called FcRn. The medicine is approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and for immune thrombocytopenia in Japan. As of February 2026, VYVGART had approvals in more than 30 countries.

Argenx reported $4.2 billion in product net sales for 2025. It sells through its own teams in the U.S., Japan, Europe and Canada, while Zai Lab licenses efgartigimod rights in Greater China in return for milestone payments and royalties.

Santa Cruz Keeps Discovery Leadership

After closing, UNP’s current leaders and employees will stay in Santa Cruz, California. The site will become argenx’s center for peptide discovery, with UNP continuing to direct its research under a strategy agreed with the buyer.

Argenx will provide clinical development and commercialization capabilities to move the prospective medicines toward patients. The purchase would add peptide research alongside an existing pipeline that includes empasiprubart, adimanebart and programs licensed to other drugmakers.

Massey said: “We want to preserve what has made UNP successful while bringing the strengths of both teams together.”

Argenx expects the acquisition to close by the end of the year.

Sources

More on argenx

All argenx (ARGX) coverage →